Greenwich LifeSciences, Inc. (GLSI) is a Stafford, Texas-based clinical-stage biopharmaceutical company with a single lead asset, GLSI-100 (GP2 plus GM-CSF), a peptide immunotherapy in a global Phase III trial called FLAMINGO-01 that aims to prevent breast cancer recurrence in HER2-positive patients after surgery. The stock traded at $20.98 in Wednesday's session, up 12.19%, or $2.28, from the prior session's close of $18.70. The direction is clearly higher, and the move follows Tuesday's 35.90% surge. The immediate reason cited by markets is the company's disclosure that two FLAMINGO-01 abstracts were accepted for publication and poster presentation at the December 8–11 San Antonio Breast Cancer Symposium, reinforced by a reiterated bullish analyst rating. No new company release of comparable weight was issued on Wednesday.
The fuel for the two-day advance came from Tuesday morning's announcement that two abstracts tied to the FLAMINGO-01 Phase III program were accepted for publication at SABCS 2026. Both posters, authored by the trial's steering committee, are scheduled for December 9 during sessions reserved for ongoing clinical trials and late-breaking abstracts. For a pre-revenue company with one program and no commercial product, a slot at a major oncology meeting functions as a scheduled catalyst: it confirms the trial is generating data the scientific community considers worth presenting and hands investors a firm date for new information.
Crucially, the release contained no efficacy figures, response rates or statistical detail, and shares nonetheless rose about 36% on Tuesday on volume more than six times normal. Wednesday's advance is best read as follow-through positioning into that date rather than a reaction to fresh disclosure. The stock opened near $18.60, dipped to $18.24, then pushed to an intraday high of $21.22, taking out Tuesday's peak of $19.28 and putting the shares at roughly $308 million in market value on about 14.7 million shares outstanding.
H.C. Wainwright reiterated its Buy rating and nudged its price target on GLSI to $70 from $69, an update framed as a model refresh following the third-quarter report. The note does not by itself justify a double-digit percentage move, and a one-dollar target adjustment is incremental. Its importance is directional: it signals that at least one covering analyst continues to carry a valuation far above the current price, which encourages momentum buyers during a news-driven run.
The rally has also been supported by sympathy flows. On Tuesday, SLS more than doubled after its Phase III peptide vaccine program in acute myeloid leukemia met its primary endpoint, a result that reframed sentiment toward peptide-based cancer vaccines as a class. Greenwich's platform sits in the same scientific family, making it a natural second-derivative beneficiary as investors searched for comparable stories. That stock traded modestly higher again on Wednesday, keeping the theme alive.
Volume has been emphatically elevated. Roughly 158,000 shares changed hands in the first 90 minutes of Wednesday's session, against a full-day average near 75,000 over the past three months — and Tuesday's turnover exceeded 548,000 shares. The broader tape offered no help: the S&P 500 slipped about 0.3%, the Nasdaq-100 was flat and the small-cap Russell 2000 was marginally higher, while the biotech ETF tracking the sector traded essentially unchanged. The divergence confirms an idiosyncratic, catalyst-driven move rather than an industry-wide bid. Technically, the stock has reclaimed levels it had not held since late October and is now well above the $13.76 close recorded on Monday, though it remains below its 52-week high of $34.10.
The score runs from 0, meaning no meaningful news and a move that is ordinary for the stock, to 100, meaning transformative news and an extreme, rare price move. GLSI earns 33 out of 100.
The verified news is real but modest relative to the company's size: a conference acceptance with no data disclosed, plus an incremental analyst target change, is not a fundamental re-rating. The price action, meanwhile, was notable without being exceptional for this name. At 12.19%, the move was about 2.5 times the stock's typical absolute daily change of roughly 4.9%, and moves of this magnitude or larger occurred only four times in the prior 69 sessions. Strong volume lifts the behavioral component, but the combination still lands in moderate territory.
The decisive event is December 9, when both posters are presented and the abstracts become public. Investors will look for recurrence data from the non-HLA-A*02 cohort, immune-response measures and any updated safety profile; design or baseline-only content would likely invite profit-taking after a two-day gain of more than 50%. The company has said posters will be posted on its website when permitted by the conference organizer.
The fundamental backdrop remains a constraint. Third-quarter results, reported Monday, showed a net loss of $5.81 million, or $0.40 per share, wider than the $0.34 consensus, with $5.9 million of cash at September 30 and language stating that continued operations depend on raising additional capital. A sharp rally raises the odds of an equity offering, which is the principal near-term risk alongside the slow cadence of recurrence events in a prevention trial. With only a small number of analysts covering the name, sentiment can shift abruptly on limited information.
Tickeron maintains hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions earn a place in its curated Trending AI Robots section. The bots differ by strategy, timeframe, performance metrics and the symbols they trade, so the lineup rotates as market conditions change. For readers tracking volatile single-name moves like this one, the page offers a practical way to see which automated strategies are currently working and how they are positioned. Reviewing it regularly can help put momentum names in a broader, rules-based context.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The 10-day moving average for GLSI crossed bearishly below the 50-day moving average on November 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 17 of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GLSI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
GLSI broke above its upper Bollinger Band on November 18, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for GLSI entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 52 of 59 cases where GLSI's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Momentum Indicator moved above the 0 level on November 17, 2026. You may want to consider a long position or call options on GLSI as a result. In 75 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for GLSI just turned positive on November 17, 2026. Looking at past instances where GLSI's MACD turned positive, the stock continued to rise in 37 of 43 cases over the following month. The odds of a continued upward trend are 86%.
GLSI moved above its 50-day moving average on November 17, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +49.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where GLSI advanced for three days, in 213 of 266 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. GLSI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 58 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: GLSI's P/B Ratio (71.438) is slightly higher than the industry average of (3.592). P/E Ratio (-9.541) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (442.120).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GLSI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology